WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2000024393) COMBINATION PRODUCT COMPRISING AN E-TYPE PROSTAGLANDIN LIGAND AND A COX-2 SELECTIVE INHIBITOR AND METHODS OF USE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2000/024393    International Application No.:    PCT/CA1999/000978
Publication Date: 04.05.2000 International Filing Date: 21.10.1999
Chapter 2 Demand Filed:    25.04.2000    
IPC:
A61K 31/365 (2006.01), A61K 45/06 (2006.01)
Applicants: MERCK FROSST CANADA & CO. [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA) (For All Designated States Except US).
CHAN, Chi, Chung [CA/CA]; (CA) (For US Only).
LABELLE, Marc [CA/CA]; (CA) (For US Only).
METTERS, Kathleen [CA/CA]; (CA) (For US Only)
Inventors: CHAN, Chi, Chung; (CA).
LABELLE, Marc; (CA).
METTERS, Kathleen; (CA)
Agent: MURPHY, Kevin, P.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA)
Priority Data:
60/105,837 23.10.1998 US
Title (EN) COMBINATION PRODUCT COMPRISING AN E-TYPE PROSTAGLANDIN LIGAND AND A COX-2 SELECTIVE INHIBITOR AND METHODS OF USE
(FR) PRODUIT DE COMBINAISON COMPRENANT UN LIGAND DE PROSTAGLANDINE DE TYPE E ET UN INHIBITEUR SELECTIF DE COX-2, ET PROCEDES D'UTILISATION DUDIT PRODUIT
Abstract: front page image
(EN)A pharmaceutical composition is disclosed which is comprised of an E-type prostaglandin ligand and a COX-2 selective inhibiting compound, in combination with a pharmaceutically acceptable carrier. Methods of treatment are also disclosed wherein an E-type prostaglandin ligand and a COX-2 selective inhibiting compound are administered in an amount that is effective to treat or prevent an E-type prostaglandin and/or COX-2 mediated disease or condition.
(FR)Composition pharmaceutique qui est composée d'un ligand de prostaglandine de type E et d'un composé inhibiteur sélectif de COX-2, en combinaison avec un excipient acceptable sur le plan pharmaceutique. La présente invention concerne également des méthodes de traitement selon lesquelles un ligand de prostaglandine de type E et un composé inhibiteur sélectif de COX-2 sont administrés en quantité efficace pour traiter ou prévenir une maladie ou un état pathologique induit par la prostaglandine de type E ou la COX-2.
Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)